JW 0105
Alternative Names: JW-0105Latest Information Update: 11 Feb 2025
At a glance
- Originator JW Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 09 Jan 2025 Preclinical trials in Unspecified in South Korea (PO)
- 01 Jan 2025 JW Pharmaceutical plans phase-I trial for Unspecified indication (In volunteers) in South Korea (PO, Tablet) in January 2025 (NCT06754943)